


Ivermectin B1a

Cat. No.:	HY-126937	
CAS No.:	71827-03-7	
Molecular Formula:	C ₄₈ H ₇₄ O ₁₄	
Molecular Weight:	875.09	
Target:	Parasite; SARS-CoV	
Pathway:	Anti-infection	
Storage:	Powder	-20°C 3 years
	In solvent	-80°C 6 months
		-20°C 1 month



BIOLOGICAL ACTIVITY

Description

Ivermectin B1a, a derivative of Avermectin B1a (HY-15308), is a main component of Ivermectin (HY-15310)^[1]. Ivermectin (MK-933) is a broad-spectrum anti-parasite agent. Ivermectin is a candidate therapeutic against SARS-CoV-2/COVID-19^[2].

In Vitro

Ivermectin belongs to the macrocyclic lactone class of avermectins and consists of a mixture of two homologous compounds, ivermectin B1a (not less than 80%) and ivermectin B1b (not more than 20%). Ivermectin B1a, the major component of Ivermectin, is inactive at a concentration of 0.3 µg/ml, whereas in the case of the minor component, ivermectin B1b, the same concentration produces 100% mortality of snails^[1]. MCE has not independently confirmed the accuracy of these methods. They are for reference only.

REFERENCES

- [1]. Naftale Kat, et al. Ivermectin Efficacy Against Biomphalaria, Intermediate Host Snail Vectors of Schistosomiasis. *J Antibiot (Tokyo)*. 2017 May;70(5):680-684.
- [2]. Khan Sharun, et al. Ivermectin, a New Candidate Therapeutic Against SARS-CoV-2/COVID-19. *Ann Clin Microbiol Antimicrob*. 2020 May 30;19(1):23.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA